What we claim is:

1. Process for the preparation of the polymorph form 1 of methyl (*S*)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4*H*-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula



I.

which comprises

a.) dissolving clopidogrel base in an "A" type solvent, adding sulfuric acid or a mixture of sulfuric acid and an "A" or "B" type solvent to the mixture, the obtained mixture containing clopidogrel hydrogensulfate is added to a mixture of a "B" type solvent containing chlopidogel hydrogensulfate polymorph form 1 as a suspension ,

or

b.) dissolving clopidogrel base in a mixture of "A" and "B" type solvents, clopidogrel hydrogensulfate polymorph form 1 is added to the solution, then adding sulfuric acid or a mixture of sulfuric acid with an "A" or "B" type solvent to the obtained mixture,

and

filtering, optionally washing and drying the formed precipitate.

2. Process according to Claim 1 which comprises using less polar aprotic, dipolar aprotic or protic solvents or mixtures thereof as "A" type solvent.

3. Process according to Claim 2 which comprises using halogenated solvents as less polar aprotic solvents, and preferably ketones as dipolar aprotic solvent.

4. Process according to Claim 3 which comprises using preferably chlorinated solvents, more preferably dichloromethane as halogenated solvents, preferably lower alkyl ketones more preferably acetone as ketone.

5. Process according to any of the claims 1-4. which comprises using aprotic, dipolar aprotic, or apolar solvents as "B" type solvent.

6. Process according to Claim 5 which comprises using ether type solvents as aprotic solvent.

7. Process according to Claim 6 which comprises using diethyl ether, tetrahydrofurane or diisopropyl ether, preferably diisopropyl ether as ether type solvent.

8. Process according to Claim 5 which comprises using saturated alkyl hydrocarbons preferably cyclohexane, hexane or heptane more preferably cyclohexane as apolar solvent.

9. Process according to Claim 5 which comprises using ester type solvent, preferably ethyl acetate as a dipolar aprotic solvent.

10. Process according to Claim 1 which comprises dissolving the clopidogrel base in dichloromethane, the obtained mixture is cooled to 0°C under stirring, adding 96 w/w% of sulfuric acid to the solution, adding the obtained mixture to a suspension of clopidogrel hydrogensulfate of the polymorph 1 form in cyclohexane at 8-10 °C, then filtering, drying the obtained precipitate.

11. Process according to Claim 1 which comprises dissolving the clopidogrel base in dichloromethane, the obtained mixture is cooled to 0°C under stirring, adding 96 w/w% of sulfuric acid to the solution, adding the obtained mixture to a suspension of clopidogrel hydrogensulfate of the polymorph 1 form in ethyl acetate at 20 °C, then filtering, drying the obtained precipitate.